HER2-targeted gold nanoparticles potentially overcome resistance to trastuzumab in gastric cancer
In conclusion, HER2-targeted AuNPs with conjugated Tmab is a promising strategy for the development of novel therapeutic agents to overcome Tmab resistance in gastric cancer. Graphical abstract
Source: Nanomedicine: Nanotechnology, Biology and Medicine - Category: Nanotechnology Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Gastric (Stomach) Cancer | Gastroenterology | HER2 | Herceptin | Nanotechnology